European researchers have identified two microRNAs, or small non-coding RNA molecules, that can be used to predict outcomes of malignant pleural mesothelioma, in an international study that…
Read More
Aggressive malignant peritoneal mesothelioma responds to treatment with Alimta (pemetrexed) and Platinol (cisplatin) chemotherapy, reports a study examining patient outcomes. But more studies are needed to…
Read More
A key approach to treating cancer these days is engineering immune T-cells to produce receptors on their surfaces that recognize cancer, so that the T-cells…
Read More
Zoledronic acid was only modestly active as a stand-alone therapy for advanced malignant pleural mesothelioma in a small Phase 2 pilot clinical trial. But researchers…
Read More
Activating a new mechanism to promote cell death could provide hope for better mesothelioma treatments, a Japanese study indicates. The research, ”Connexin 43 enhances Bax…
Read More
Combining immunotherapy, accelerated radiation and surgery can improve immune system response against malignant pleural mesothelioma, according to a study. Immunotherapies for solid tumors have become a…
Read More
A study that looked into France’s RENAPE Observational Registry, a database of rare peritoneal tumors, found that the presence of programmed death-ligand 1 (PD-L1) on…
Read More
It is safe for malignant mesothelioma patients to combine Tremelimumab and Imfinzi (durvalumab), according to a study to be presented at the 2017 American Society of Clinical…
Read More
A new study reports that a protein formerly identified as a potential therapeutic target in pleural mesothelioma, CXCR4, might not be a relevant approach for the…
Read More
Researchers found that a protein with anti-cancer activity, which is isolated from the bullfrog, may be a good treatment option for mesothelioma, including in standard-of-care…
Read More
